Litcius/Paper detail

The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials

Brandon Essink, Laurence Chu, William Seger, Elizabeth Barranco, Nancy Le Cam, Hamilton Bennett, Veronica Faughnan, Rolando Pajón, Yamuna Devi Paila, Brooke Bollman, Steven Wang, Jacqueline Dooley, Shiva Kalidindi, Brett Leav

2023The Lancet Infectious Diseases141 citationsDOI

Topics & Concepts

MedicinePlaceboImmunogenicityClinical trialFlavivirusZika virusVirologyInternal medicineRandomized controlled trialImmunologyVirusAntibodyPathologyAlternative medicineMosquito-borne diseases and controlVirology and Viral DiseasesBiological Research and Disease Studies
The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials | Litcius